impact factor, citescore

Full Papers


A first-in-human, double-blind, randomised, placebo-controlled, dose ascending study of intra-articular rhFGF18 (sprifermin) in patients with advanced knee osteoarthritis

1, 2, 3, 4, 5, 6, 7, 8


  1. Department of Clinical Sciences Lund, Orthopaedics, Lund University, Lund, Sweden.
  2. EMD Serono Research and Development Institute, Billerica, MA, USA.
  3. EMD Serono Research and Development Institute, Billerica, MA, USA.
  4. Global Research and Development, Merck KGaA, Darmstadt, Germany.
  5. Department of Orthopaedics/Surgery, Kungälv Sjukhus, Kungälv, Sweden.
  6. Department of Orthopaedic Surgery, Regionshospitalet Viborg, Viborg, Denmark.
  7. Global Research and Development, Merck KGaA, Darmstadt, Germany.
  8. Department of Applied Physics, University of Eastern Finland, Kuopio, Finland.

2016 Vol.34, N°3
PI 0445, PF 0450
Full Papers

Free to view
(click on article PDF icon to read the article)

PMID: 27050139 [PubMed]

Received: 15/05/2015
Accepted : 23/11/2015
In Press: 23/03/2016
Published: 30/05/2016


To evaluate the safety of intra-articular sprifermin (primary), and to evaluate systemic exposure, biomarkers, histology, and other cartilage parameters in patients with advanced osteoarthritis (OA).
This was a first-in-human, double-blind, randomised, placebo-controlled trial of single and multiple ascending doses of sprifermin from 3–300 μg in knee OA patients scheduled for total knee replacement. Patients were randomised 3:1 to sprifermin or placebo, injected into the target knee once or once weekly for 3 weeks, and followed-up for 24 weeks.
Fifty-five patients were treated with sprifermin, 25 with single and 30 with multiple doses, 18 received placebo. There was no clear difference between the active and placebo groups in incidence, severity, and nature of reported treatment emergent adverse events. Acute inflammatory reactions were slightly more common with sprifermin 300 μg, but none led to discontinuation. No clear difference was seen between placebo and sprifermin in physician-assessed local tolerability, pain, or swelling in the knee. No meaningful changes over time, or differences between treatment groups, were observed for safety laboratory parameters or ECG. Although individual abnormalities were observed, no patterns were evident suggesting a relation to treatment or potential safety concern. No systemic sprifermin exposure, anti-FGF18 antibodies, or clear-cut effects on systemic biomarkers were detected.
This first clinical trial of sprifermin revealed no serious safety concerns, although larger studies are needed. The possibility of positive effects of intra-articular sprifermin on histological and other cartilage parameters in knee OA also warrant further investigation.

Rheumatology Article

Rheumatology Addendum